These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

223 related items for PubMed ID: 12071935

  • 1. De novo acute myeloid leukemia with multilineage dysplasia: treatment results and prognostic evaluation from a series of 44 patients treated with fludarabine, cytarabine and G-CSF (FLAG).
    Ferrara F, Palmieri S, Pocali B, Pollio F, Viola A, Annunziata S, Sebastio L, Schiavone EM, Mele G, Gianfaldoni G, Leoni F.
    Eur J Haematol; 2002 Apr; 68(4):203-9. PubMed ID: 12071935
    [Abstract] [Full Text] [Related]

  • 2. Fludarabine, cytarabine, and G-CSF (FLAG) for the treatment of acute myeloid leukemia relapsing after autologous stem cell transplantation.
    Ferrara F, Melillo L, Montillo M, Leoni F, Pinto A, Mele G, Mirto S.
    Ann Hematol; 1999 Aug; 78(8):380-4. PubMed ID: 10460353
    [Abstract] [Full Text] [Related]

  • 3. Fludarabine, cytarabine, and granulocyte-colony stimulating factor for the treatment of high risk myelodysplastic syndromes.
    Ferrara F, Leoni F, Pinto A, Mirto S, Morra E, Zagonel V, Mele G, Ciolli S, Magrin S, Montillo M.
    Cancer; 1999 Nov 15; 86(10):2006-13. PubMed ID: 10570425
    [Abstract] [Full Text] [Related]

  • 4. IDA-FLAG (idarubicin, fludarabine, cytarabine, G-CSF), an effective remission-induction therapy for poor-prognosis AML of childhood prior to allogeneic or autologous bone marrow transplantation: experiences of a phase II trial.
    Fleischhack G, Hasan C, Graf N, Mann G, Bode U.
    Br J Haematol; 1998 Aug 15; 102(3):647-55. PubMed ID: 9722289
    [Abstract] [Full Text] [Related]

  • 5. [IDA-FLAG (idarubicin, fludarabine, high dosage cytarabine and G-CSF)--an effective therapy regimen in treatment of recurrent acute myelocytic leukemia in children and adolescents. Initial results of a pilot study].
    Fleischhack G, Graf N, Hasan C, Ackermann M, Breu H, Zernikow B, Bode U.
    Klin Padiatr; 1996 Aug 15; 208(4):229-35. PubMed ID: 8926688
    [Abstract] [Full Text] [Related]

  • 6. Treatment of "poor risk" acute myeloid leukemia with fludarabine, cytarabine and G-CSF (flag regimen): a single center study.
    Carella AM, Cascavilla N, Greco MM, Melillo L, Sajeva MR, Ladogana S, D'Arena G, Perla G, Carotenuto M.
    Leuk Lymphoma; 2001 Jan 15; 40(3-4):295-303. PubMed ID: 11426551
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Autologous stem cell transplantation after complete remission and first consolidation in acute myeloid leukemia patients aged 61-70 years: results of the prospective EORTC-GIMEMA AML-13 study.
    Thomas X, Suciu S, Rio B, Leone G, Broccia G, Fillet G, Jehn U, Feremans W, Meloni G, Vignetti M, de Witte T, Amadori S.
    Haematologica; 2007 Mar 15; 92(3):389-96. PubMed ID: 17339189
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Salvage therapy for acute myeloid leukemia with fludarabine, cytarabine, and idarubicin with or without gemtuzumab ozogamicin and with concurrent or sequential G-CSF.
    Martin MG, Augustin KM, Uy GL, Welch JS, Hladnik L, Goyal S, Tiwari D, Monahan RS, Reichley RM, Cashen AF, Stockerl-Goldstein K, Westervelt P, Abboud CN, Dipersio JF, Vij R.
    Am J Hematol; 2009 Nov 15; 84(11):733-7. PubMed ID: 19806665
    [Abstract] [Full Text] [Related]

  • 11. A multicentre, open, non-comparative phase II study of a combination of fludarabine phosphate, cytarabine and granulocyte colony-stimulating factor in relapsed and refractory acute myeloid leukaemia and de novo refractory anaemia with excess of blasts in transformation.
    Jackson G, Taylor P, Smith GM, Marcus R, Smith A, Chu P, Littlewood TJ, Duncombe A, Hutchinson M, Mehta AB, Johnson SA, Carey P, MacKie MJ, Ganly PS, Turner GE, Deane M, Schey S, Brookes J, Tollerfield SM, Wilson MP.
    Br J Haematol; 2001 Jan 15; 112(1):127-37. PubMed ID: 11167793
    [Abstract] [Full Text] [Related]

  • 12. Treatment of relapse after allogeneic bone marrow transplantation with reduced intensity conditioning (FLAG +/- Ida) and second allogeneic stem cell transplant.
    Pawson R, Potter MN, Theocharous P, Lawler M, Garg M, Yin JA, Rezvani K, Craddock C, Rassam S, Prentice HG.
    Br J Haematol; 2001 Dec 15; 115(3):622-9. PubMed ID: 11736947
    [Abstract] [Full Text] [Related]

  • 13. A phase I-II study of plerixafor in combination with fludarabine, idarubicin, cytarabine, and G-CSF (PLERIFLAG regimen) for the treatment of patients with the first early-relapsed or refractory acute myeloid leukemia.
    Martínez-Cuadrón D, Boluda B, Martínez P, Bergua J, Rodríguez-Veiga R, Esteve J, Vives S, Serrano J, Vidriales B, Salamero O, Cordón L, Sempere A, Jiménez-Ubieto A, Prieto-Delgado J, Díaz-Beyá M, Garrido A, Benavente C, Pérez-Simón JA, Moscardó F, Sanz MA, Montesinos P, CETLAM and PETHEMA groups.
    Ann Hematol; 2018 May 15; 97(5):763-772. PubMed ID: 29392425
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Fludarabine, cytarabine, and G-CSF (FLAG) for the treatment of poor risk acute myeloid leukemia.
    Montillo M, Mirto S, Petti MC, Latagliata R, Magrin S, Pinto A, Zagonel V, Mele G, Tedeschi A, Ferrara F.
    Am J Hematol; 1998 Jun 15; 58(2):105-9. PubMed ID: 9625576
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. FLAG-IDA in the treatment of refractory/relapsed acute myeloid leukemia: single-center experience.
    Pastore D, Specchia G, Carluccio P, Liso A, Mestice A, Rizzi R, Greco G, Buquicchio C, Liso V.
    Ann Hematol; 2003 Apr 15; 82(4):231-5. PubMed ID: 12707726
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Fludarabine, cytarabine, granulocyte colony-stimulating factor, and idarubicin (FLAG-IDA) for the treatment of children with poor-prognosis acute leukemia: the Hacettepe experience.
    Tavil B, Aytac S, Balci YI, Unal S, Kuskonmaz B, Yetgin S, Gurgey A, Tuncer M, Gumruk F, Uckan D, Cetin M.
    Pediatr Hematol Oncol; 2010 Oct 15; 27(7):517-28. PubMed ID: 20677923
    [Abstract] [Full Text] [Related]

  • 20. FLAG (fludarabine + high-dose cytarabine + G-CSF): an effective and tolerable protocol for the treatment of 'poor risk' acute myeloid leukemias.
    Visani G, Tosi P, Zinzani PL, Manfroi S, Ottaviani E, Testoni N, Clavio M, Cenacchi A, Gamberi B, Carrara P.
    Leukemia; 1994 Nov 15; 8(11):1842-6. PubMed ID: 7526088
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.